Clinical trial of a potent non-halogenated topical steroid, Budesonide
DOI:
https://doi.org/10.2340/0001555561180182Abstract
In a double-blind, randomized multi-centre study, 116 patients with psoriasis have been treated for 1-3 weeks with budesonide ointment (Preferid, Draco/Tika; a subsidiary of AB ASTRA), a new non-halogenated topical steroid. In a series of 11 patients a 0.025% budesonide ointment was significantly superior to placebo. In a second series, of 54 patients, a 0.025% fluocinolone acetonide ointment (Synalar, ICI). In a third series, of 51 patients, a 0.010% budesonide ointment was compared with 0.025% fluocinolone acetonide ointment. No statistically significant difference between these two preparations was found to exist. No adverse reactions were observed.Downloads
Download data is not yet available.
Downloads
Published
1981-03-01
How to Cite
Agrup, G., Björnberg, A., Elmros, T., Groth, O., Hannuksela, M., Lassus, A., … Thomsen K. (1981). Clinical trial of a potent non-halogenated topical steroid, Budesonide. Acta Dermato-Venereologica, 61(2), 180–182. https://doi.org/10.2340/0001555561180182
Issue
Section
Articles
License
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
